Catalent (CTLT)
(Delayed Data from NYSE)
$56.39 USD
+0.18 (0.32%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $56.38 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 101 - 120 ( 216 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Quarter in Line, but Healthy (Higher Guide) Outlook Ahead
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
4Q Earnings with M&A Announcement Driving Higher Growth and Margins
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools - Vaccine, Bioproduction, mRNA, Cell & Gene Therapy and M&A: 2H21 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Raising Estimates - mRNA and Biologics Building Revenue and Expanding Multiple
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Inaugural Life Sciences & MedTech Conference: Key Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools: Hard and Soft Landings for COVID-19 Diagnostics and Vaccines
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department